eLifeBioengineeringPeer-reviewed journal article
Targeted Computational Design of an Interleukin-7 Superkine with Enhanced Folding Efficiency and Immunotherapeutic Efficacy
See-Khai LimiD, Wen‐Ching Lin, Yi‐Chung Pan, Sin‐Wei HuangiD, Yao‐An Yu, Cheng-Hung ChangiD, Che‐Ming Jack HuiD, Chung‐Yuan MouiD, Kurt Yun MouiD
Abstract
Interleukin-7 (IL-7) plays a central role in maintaining T cell development and immune homeostasis, and enhancing the cytokines immune-stimulatory functionality has broad therapeutic implications against various oncological malignancies. Herein, we show a computationally designed IL7 superkine, Neo-7, which exhibits enhanced folding efficiency and superior binding affinity to its cognate receptors. To streamline the protein candidate prediction and validation process, the loop region of IL7 was strategically targeted for redesign while most of the receptor-interacting regions were preserved. Leveraging advanced computational tools such as AlphaFold2, we show loop remodeling to rectify structural irregularities that allows for iterative stabilization of protein backbone and leads to identification of beneficial mutations conducive to receptor engagement. Neo-7 superkine shows improved thermostability and production yield, and it exhibits heightened immune-stimulatory and anticancer effect in C57BL/6J mice. These findings underscore the utility of a targeted computational approach for de novo cytokine development.
- organism: mouse
- assay: protein structure
- research focus: drug response / drug discovery
- approach: deep learning
- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 0th percentile
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- High-Throughput De Novo Protein Design Yields Novel Immunomodulatory Agonists
Mohamad H. Abedi, Marc Expòsit, … David A. Baker·bioRxiv·Oct 12, 2025
- A mechanistically novel peptide agonist of the IL-7 receptor that addresses limitations of IL-7 cytokine therapy
W. J. Dower, A. I. Park, … R. W. Barrett·bioRxiv·May 24, 2023
- Engineered cytokine/antibody fusion proteins improve delivery of IL-2 to pro-inflammatory cells and promote antitumor activity
E. K. Leonard, J. Tomala, … J. B. Spangler·bioRxiv·May 3, 2023
- Rational Design of Selective IL-2-based Activators for CAR T Cells Using AlphaFold3 and Physics-Informed Machine Learning
Zakaria Larbi Dahmani, Anupam Banerjee·bioRxiv·Mar 12, 2026
- Directed disruption of IL2 aggregation sites produces designer biologics with enhanced specificity coupled to improved production capacity
A. J. Dashwood, Ntombizodwa Makuyana, … Adrian Liston·Computational and Structural Biotechnology JournalPeer-reviewed·Jan 1, 2025
- A Dynamically Regulated Designed IL-2 for Tumor-localized Signaling
Howell F. Moffett, Brian D. Weitzner, … Marc J. Lajoie·bioRxiv·Sep 22, 2026